Beobachten
- Pressemitteilung BoxID 516071
ProBioGen Introduces Novel Productivity-Boosting Technology for Therapeutic Protein Production: "Pathway Modulator"
(PresseBox) (Berlin, )
ProBioGen announced the implementation of its new "Pathway Modulator Technology", a permanent modification of animal cell lines for substantially improved protein yields. The Pathway Modulator Technology is royalty-free and available for new and existing cell lines either in service projects or as a license.
The Pathway Modulator Technology is highly versatile and quick: It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes' concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.
The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.
The Pathway Modulator Technology can be freely combined with other parts of ProBioGen's Tool Box, including the GlymaxX® ADCC Enhancement Technology, the stable CHO Evaluation Platform with DG44 and K1 cell lines, and the companies' Full Pharmaceutical CHO Expression and Media Platform.
ProBioGen is actively seeking biopharmaceutical companies with hard-to-make protein drugs or with cell lines of insufficient productivities, to challenge their current yields.
The Pathway Modulator Technology is highly versatile and quick: It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes' concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.
The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.
The Pathway Modulator Technology can be freely combined with other parts of ProBioGen's Tool Box, including the GlymaxX® ADCC Enhancement Technology, the stable CHO Evaluation Platform with DG44 and K1 cell lines, and the companies' Full Pharmaceutical CHO Expression and Media Platform.
ProBioGen is actively seeking biopharmaceutical companies with hard-to-make protein drugs or with cell lines of insufficient productivities, to challenge their current yields.
Über ProBioGen AG
ProBioGen is an internationally operating technology provider and Contract Development and Manufacturing Organization (CDMO) with almost 20 years of experience in cell culture, process development, and GMP-manufacturing. ProBioGen, with its scientific excellence and strong intellectual property base, is a competent and reliable CDMO partner, offering customized solutions for even the most challenging development and manufacturing requirements. This is backed by the company's established, fee-for-service-based CHO cell and media platform, and its innovative platform technologies, such as GlymaxX® ADCC enhancement technology, the pathway modulator technology as well as the AGE1 family of animal and human designer cell lines, as well as its comprehensive portfolio of cell-based activity assays. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen was founded 1994 and is located in Berlin, Germany.
Diese Pressemitteilungen könnten Sie auch interessieren
|
Roche's Rapid Mycoplasma Detection Test MycoTOOL Receives Acceptance from Canadian Authorities for Release Testing of Biopharmaceutical Roche Product
, Biotechnik, Roche Diagnostics GmbH
Today Roche announced that the Canadian Health Authority has accepted the use of its PCR based mycoplasma detection test MycoTOOL for release testing of one of Roche's...
|
Rohstofflieferant Meer
Eine sichere Rohstoffversorgung ist für die deutsche Industrie von existenzieller Bedeutung. Aufgrund der stetig wachsenden Nachfrage von Rohstoffen stellt der Abbau...
|
|
Roche Launches New Bead Based DNA Target Enrichment Reagent Kit for Next Generation Sequencing
, Biotechnik, Roche Diagnostics GmbH
Roche today announced the global launch of its SeqCap EZ Pure Capture Bead Kit supporting target enrichment workflows prior to DNA sequencing. The newly introduced...
